Literature DB >> 22386762

Accumulation of oocytes: a new strategy for managing low-responder patients.

A Cobo1, Nicolás Garrido, Juana Crespo, Remohí José, Antonio Pellicer.   

Abstract

Accumulation of oocytes from several ovarian stimulation cycles is currently possible using novel vitrification technologies. This strategy could increase the inseminated cohort, creating a similar situation to normoresponders. This study included 242 low-responder (LR) patients (594 cycles) whose mature oocytes were accumulated by vitrification and inseminated simultaneously (LR-Accu-Vit) and 482 patients (588 cycles) undergoing IVF/embryo transfer with fresh oocytes in each stimulation cycle (LR-fresh). Drop-out rate in the LR-fresh group was >75%. The embryo-transfer cancellation per patient was significantly lower in the LR-Accu-Vit group (9.1%) than the LR-fresh group (34.0%). Live-birth rate (LBR)/patient was higher in the LR-Accu-Vit group (30.2%) than the LR-fresh group (22.4%). Cumulative LBR/patient was statistically higher in the LR-Accu-Vit group (36.4%) than the LR-fresh group (23.7%) and a similar outcome was observed among patients aged ⩾40years (LR-Accu-Vit 15.8% versus LR-fresh 7.1%). The LR-Accu-Vit group had more cycles with embryo cryopreservation (LR-Accu-Vit 28.9% versus LR-fresh 8.7%). Accumulation of oocytes by vitrification and simultaneous insemination represents a successful alternative for LR patients, yielding comparable success rates to those in normoresponders and avoiding adverse effects of a low response. The accumulation of oocytes from several ovarian stimulation cycles is currently possible with the aid of novel vitrification technologies. This strategy could be useful for low-responder patients, contributing to increase the inseminated cohort and creating a similar situation as in normal responders. According to the results presented herein (higher live-birth rate per patient treated), this strategy represents a successful alternative for low-responder patients, yielding comparable success rates to those in normal responders and avoiding the adverse effects of a low response.
Copyright © 2012 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22386762     DOI: 10.1016/j.rbmo.2011.12.012

Source DB:  PubMed          Journal:  Reprod Biomed Online        ISSN: 1472-6483            Impact factor:   3.828


  29 in total

1.  Morphokinetics analysis of embryos derived from vitrified/warmed oocytes.

Authors:  D Montjean; C Geoffroy-Siraudin; M Gervoise-Boyer; P Tourame; P Boyer
Journal:  J Assist Reprod Genet       Date:  2015-09-26       Impact factor: 3.412

2.  Accumulation of oocytes from a few modified natural cycles to improve IVF results: a pilot study.

Authors:  Ermanno Greco; Katarzyna Litwicka; Cristiana Arrivi; Maria Teresa Varricchio; Daniela Zavaglia; Cecilia Mencacci; Maria Giulia Minasi
Journal:  J Assist Reprod Genet       Date:  2013-11       Impact factor: 3.412

3.  Meta-analysis of GnRH-antagonists versus GnRH-agonists in poor responder protocols.

Authors:  Myrto Papamentzelopoulou; Sofoklis Stavros; Despoina Mavrogianni; Christos Kalantzis; Dimitrios Loutradis; Petros Drakakis
Journal:  Arch Gynecol Obstet       Date:  2021-01-10       Impact factor: 2.344

4.  A combination of hydroxypropyl cellulose and trehalose as supplementation for vitrification of human oocytes: a retrospective cohort study.

Authors:  Aila Coello; Pilar Campos; José Remohí; Marcos Meseguer; Ana Cobo
Journal:  J Assist Reprod Genet       Date:  2016-01-11       Impact factor: 3.412

5.  The first 50 live births after autologous oocyte vitrification in France.

Authors:  Any Beltran Anzola; Vanessa Pauly; Cendrine Geoffroy-Siraudin; Marie-José Gervoise-Boyer; Debbie Montjean; Pierre Boyer
Journal:  J Assist Reprod Genet       Date:  2015-10-30       Impact factor: 3.412

Review 6.  The state of "freeze-for-all" in human ARTs.

Authors:  Natalia Basile; Juan A Garcia-Velasco
Journal:  J Assist Reprod Genet       Date:  2016-09-14       Impact factor: 3.412

7.  Second stimulation in the same ovarian cycle: an option to fully-personalize the treatment in poor prognosis patients undergoing PGT-A.

Authors:  Alberto Vaiarelli; Danilo Cimadomo; Gianluca Gennarelli; Maurizio Guido; Carlo Alviggi; Alessandro Conforti; Claudia Livi; Alberto Revelli; Silvia Colamaria; Cindy Argento; Maddalena Giuliani; Carlo De Angelis; Maria Matteo; Stefano Canosa; Angela D'Alfonso; Valentino Cimadomo; Laura Rienzi; Filippo Maria Ubaldi
Journal:  J Assist Reprod Genet       Date:  2022-02-07       Impact factor: 3.412

Review 8.  Current trends and progress in clinical applications of oocyte cryopreservation.

Authors:  Aylin P Cil; Emre Seli
Journal:  Curr Opin Obstet Gynecol       Date:  2013-06       Impact factor: 1.927

Review 9.  ART outcomes following ovarian stimulation in the luteal phase:a systematic review and meta-analysis.

Authors:  Buo-Jia Lu; Chien-Ju Lin; Bou-Zenn Lin; Li Huang; Li-Ting Chien; Chi-Huang Chen
Journal:  J Assist Reprod Genet       Date:  2021-05-25       Impact factor: 3.357

10.  New tools for embryo selection: comprehensive chromosome screening by array comparative genomic hybridization.

Authors:  Lorena Rodrigo; Emilia Mateu; Amparo Mercader; Ana Cristina Cobo; Vanessa Peinado; Miguel Milán; Nasser Al-Asmar; Inmaculada Campos-Galindo; Sandra García-Herrero; Pere Mir; Carlos Simón; Carmen Rubio
Journal:  Biomed Res Int       Date:  2014-04-29       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.